OnKure

OnKure (formerly Reneo) was focused on the development of therapies for patients with rare genetic mitochondrial diseases. Reneo Therapeutics merged with OnKure, a precision medicine company that is targeting biologically validated drivers of cancers and vascular anomalies that are underserved by available therapies. In 2024 and the company is listed on Nasdaq with the ticker: OKUR